glp 1 agonist eli lilly FDA just approved orforglipron (Foundayo), Lilly's oral GLP-1 receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest eli lilly glp-1 news FDA

Cellular and molecular mechanisms of the bloodbrain barrier dysfunction in neurodegenerative diseases

Our complete retatrutide dosing guide covers monotherapy protocols in detail

A major analysis of the effects of ALCAR on older adults suffering from Mild Cognitive Impairment (MCI) and early-stage Alzheimer's disease found that administering 1.5 to 3 grams of ALCAR per day for 3 to 12 months resulted in significant improvements across multiple cognitive function metrics, clinical scales, and psychometric tests compared to placebos

ASMBS B12 Recommendations for People after Bariatric Surgery Appendix G

The overall gene expression pattern shifted cells from a profile associated with diseased or damaged tissue toward a healthier state